Clinical Trial

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-26; most recent amendment 2026-02-17.
Status change: Not Yet Recruiting → Recruiting 2025-02-28
Trial Details
NCT Number NCT06616597
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: United States Department of Defense, Prostate Cancer Foundation
Conditions Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Enrollment 58 participants
Start Date 2025-02-13
Primary Completion 2031-03-30 (estimated)
Study Completion 2032-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-19